LOS ANGELES, Aug. 1, 2019 /PRNewswire/ -- Arosa+LivHOME has agreed to acquire The Cameron Group, a leading provider of care management and home care services in Orlando, Florida, pending regulatory and licensure approval. This will mark Arosa+LivHOME's fifth acquisition since January and entry into its fifth state. 

ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ -- Of the two-thirds of Americans who have been prescribed a medication, 50 percent of them don't take their drugs as prescribed1 largely because of the high cost of the drugs and sticker shock at the pharmacy. Twenty to 30 percent of prescriptions are never even filled.2 The impact ripples through heal

SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb's Opdivo® (nivolumab) f

Dermatology.com Supports Lower, Predictable Pricing for Many of Bausch Health's Prescription Dermatology Products at Walgreens 9,500 Retail Pharmacies DEERFIELD, Ill. and LAVAL, Quebec, Aug. 1, 2019 /PRNewswire/ -- Walgreens and Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced a modification t

CAMBRIDGE, Mass., Aug. 1, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided a business update for the quarter ended June 30, 2019.

CAMBRIDGE, Mass., Aug. 1, 2019 /PRNewswire/ -- EIP Pharma, Inc., a CNS-focused therapeutics company, today announced that company management will present at the Canaccord Genuity 39th Annual Growth Conference on Thursday, August 8, 2019, at 12:00 p.m. ET in Boston, MA. 

ROCKVILLE, Md., Aug. 1, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the micr

SAN DIEGO, Aug. 1, 2019 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the German Federal Ministry of Education and Research has awarded its subsidiary,

WESTBROOK, Maine, Aug. 1, 2019 /PRNewswire/ --Reports revenue growth of 7% on a reported basis and 9% on an organic basis, driven by Companion Animal Group ("CAG") Diagnostics recurring revenue growth of 9% reported and 11% organic Delivers EPS of $1.43, representing 16% growth on a reported basis and 19% on a comparable co

NEW YORK, Aug. 1, 2019 /PRNewswire/ -- The global health organization Helen Keller International has announced the appointment of Dr. Emmanuel d'Harcourt as its new Chief Program and Innovation Officer.